CN Patent

CN110526916B — 氘代Capmatinib化合物及其用途

Assigned to Haichuang Pharmaceutical Co Ltd · Expires 2021-07-13 · 5y expired

What this patent protects

本发明公开了氘代Capmatinib化合物及其用途，具体公开了式(I)所示的化合物或其光学异构体、药学上可接受的盐、水合物或溶剂合物，其中，R 1 ‑R 16 分别独立选自H、D，且不全为H。本发明提供的各种化合物及其盐类、水合物或溶剂合物，具备抗癌活性和更好的代谢稳定性和药代动力学性质，应用前景优良。

USPTO Abstract

本发明公开了氘代Capmatinib化合物及其用途，具体公开了式(I)所示的化合物或其光学异构体、药学上可接受的盐、水合物或溶剂合物，其中，R 1 ‑R 16 分别独立选自H、D，且不全为H。本发明提供的各种化合物及其盐类、水合物或溶剂合物，具备抗癌活性和更好的代谢稳定性和药代动力学性质，应用前景优良。

Drugs covered by this patent

capmatinib-hydrochloride (CAPMATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN110526916B
Jurisdiction: CN
Classification: —
Expires: 2021-07-13
Drug substance claim: No
Drug product claim: No
Assignee: Haichuang Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.